Evidence map›Paper›PMID 31622786›Full record

ArticleCellular and molecular gastroenterology and hepatology2020

Down-regulation of RalGTPase-Activating Protein Promotes Colitis-Associated Cancer via NLRP3 Inflammasome Activation.

Tomoya Iida, Daisuke Hirayama, Naoki Minami, Minoru Matsuura, Kohei Wagatsuma, Kentaro Kawakami, Kanna Nagaishi, Masanori Nojima, Hiroki Ikeuchi, Seiichi Hirota and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cellular and molecular gastroenterology and hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. RalGAPα2 and NLRP3 Orchestrate Tumor Invasion in Colitis-Associated Cancers.Cellular and molecular gastroenterology and hepatology · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Tomoya IidaDepartment of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Daisuke HirayamaDepartment of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Naoki MinamiDepartment of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Minoru MatsuuraDepartment of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Kohei WagatsumaDepartment of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Kentaro KawakamiDepartment of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Kanna NagaishiSecond Department of Anatomy, Sapporo Medical University School of Medicine, Sapporo, Japan.
Masanori NojimaCenter for Translational Research, The Institute of Medical Science Hospital, The University of Tokyo, Tokyo, Japan.
Hiroki IkeuchiDivision of Lower Gastrointestinal, Department of Surgery, Hyogo College of Medicine, Nishinomiya, Japan; Inflammatory Bowel Disease Center, Hyogo College of Medicine, Nishinomiya, Japan.
Seiichi HirotaDepartment of Surgical Pathology, Hyogo College of Medicine, Nishinomiya, Japan.
Ryutaro ShirakawaDepartment of Molecular and Cellular Biology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan.
Hisanori HoriuchiDepartment of Molecular and Cellular Biology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan.
Hiroshi NakaseDepartment of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan. Electronic address: hiropynakase@gmail.com.
Sapporo Medical University · JPHyogo Medical University · JPKyoto University · JPTohoku University · JPThe University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

aimsRal guanosine triphosphatase-activating protein α2 (RalGAPα2) is the major catalytic subunit of the negative regulators of the small guanosine triphosphatase Ral, a member of the Ras subfamily. Ral regulates tumorigenesis and invasion/metastasis of some cancers; however, the role of Ral in colitis-associated cancer (CAC) has not been investigated. We aimed to elucidate the role of Ral in the mechanism of CAC.

methodsWe used wild-type (WT) mice and RalGAPα2 knockout (KO) mice that showed Ral activation, and bone marrow chimeric mice were generated as follows: WT to WT, WT to RalGAPα2 KO, RalGAPα2 KO to WT, and RalGAPα2 KO to RalGAPα2 KO mice. CAC was induced in these mice by intraperitoneal injection of azoxymethane followed by dextran sulfate sodium intake. Intestinal epithelial cells were isolated from colon tissues, and we performed complementary DNA microarray analysis. Cytokine expression in normal colon tissues and CAC was analyzed by quantitative polymerase chain reaction.

resultsBone marrow chimeric mice showed that immune cell function between WT mice and RalGAPα2 KO mice was not significantly different in the CAC mechanism. RalGAPα2 KO mice had a significantly larger tumor number and size and a significantly higher proportion of tumors invading the submucosa than WT mice. Higher expression levels of matrix metalloproteinase-9 and matrix metalloproteinase-13 were observed in RalGAPα2 KO mice than in WT mice. The expression levels of interleukin 1β, NLRP3, apoptosis associated speck-like protein containing a CARD, and caspase-1 were apparently increased in the tumors of RalGAPα2 KO mice compared with WT mice. NLRP3 inhibitor reduced the number of invasive tumors.

conclusionsRal activation participates in the mechanism of CAC development via NLRP3 inflammasome activation.

Indexed as

AnimalsAzoxymethaneColitis-Associated NeoplasmsColonDown-RegulationGTPase-Activating ProteinsHumansInflammasomesIntestinal MucosaMaleMiceMice, KnockoutNeoplasms, ExperimentalNLR Family, Pyrin Domain-Containing 3 Proteinral GTP-Binding ProteinsAzoxymethaneGTPase-Activating ProteinsInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, mouseRalgapa2 protein, mouseral GTP-Binding ProteinsColitis-Associated CancerNLRP3 InflammasomeRalRal-GTPase Activating Protein (RalGAP)

Identifiers

PMID31622786
PMCPMC6957823
OpenAlexW2980629175

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.